Sign Up
OverviewAPI
CSL Limited's phase 3 AEGIS-II trial resulted in disappointing results, failing to meet its primary efficacy endpoint for CSL112 in reducing major cardiovascular events. No near-term regulatory filing plans and no significant financial impact expected. The company advises caution in investment decisions due to high p/e ratio.

Ask a question